Skip to main content
. 2021 Jan 1;9(1):E87–E95. doi: 10.1055/a-1300-1085

Table 1. Spreadsheet reporting the characteristics of all studies included.

Study Year Study design Duration Procedure Age (years) Mean preoperative BMI Total number of patients Sex Patient 12-month follow-up 12 months %EWL Adverse events 1 NIH Quality Assesment Tool
Alqahtani A. 38 2019 Observational 18 months ESG 344 ± 95 333 ± 45 1000 M103 F897 216 675 ± 523 Major AE 6; minor AE 961 8/12
Lopez-Nava G. 39 2017 Observational 2 years ESG 449 ± 95 383 ± 55 154 M46 F108 64 526 ± 313 Major AE 0; minor AE N/R 10/12
Barrichello S. 40 2019 Observational 1 year ESG 423 ± 96 341 ± 3 193 (165) 2 M45 (36) 2 F148 (129) 2 121 594 ± 257 Major AE 2; minor AE 103 10/12
Abu Dayyeh B. K. 41 2017 Observational 20 months ESG 47 ± 10 355 ± 26 25 M4 F21 25 54 ± 40 Major AE 2; minor AE 18 11/12
James T. W. 28 2019 Observational 1 year ESG 45 ± 9 384 ± 54 100 M14 F86 100 661 ± 215 Major AE 2; minor AE 2 10/12
Grau Morales J. 42 2018 Observational 1 year ESG 415 ± 10 351 ± 55 148 M27 F121 148 754 ± 85 Major AE 0; minor AE 2 11/12
Bhandari M. 29 2019 Observational 1 year ESG 405 ± 138 348 ± 52 53 M10 F43 42 662 ± 255 Major AE 0; minor AE 47 11/12
Cheskin L. J. 30 2020 Observational 1 year ESG 480 ± 121 400 ± 77 105 M30 F75 43 57 ± 259 Major AE 1; minor AE 4 9/12
Berry M. A. 27 2018 Observational 56 months LSG 39 ± 117 3239 ± 12 252 M64 F188 219 97 ± 214 Major AE3; minor AE 3 11/12
Noun R. 32 2012 Observational 2 years LSG 33 ± 10 332 ± 25 122 M17 F105 122 765 ± 17 Major AE 0; minor AE 4 9/12
Maiz C. 36 2015 Observational 1 year LSG 372 ± 111 331 ± 18 836 M107 F729 557 1072 ± 371 Major AE 66; minor AE 33 9/12
Zhang Y. 31 2014 Randomized Controlled Trial 5 years LSG 293 ± 98 385 ± 42 32 M12 F20 26 739 ± 243 Major AE 0; minor AE 4 4/5 3
Ismail M. 33 2019 Observational 7 years LSG 337 ± 112 376 ± 16 95 (35) 2 M43 F52 90 (35) 2 686 ± 27 Major AE 0; minor AE N/R 11/12
Hans P. K. 34 2018 Observational 5 years LSG 299 ± 73 383 ± 62 218 M68 F150 96 628 ± 169 Major AE 0; minor AE 35 8/12
Park Y. H. 35 2017 Observational 2 years LSG 304 ± 79 347 ± 53 74 M16 F58 74 878 ± 251 Major AE 5; minor AE 6 8/12
Lakdawala M. 37 2015 Observational 2 years LSG 355 ± 78 399 ± 51 300 M150 F150 300 683 ± 24 Major AE 0; minor AE 1 10/12

AE, adverse events; ESG, endoscopic sleeve gastroplasty; LSG, laparoscopic sleeve gastrectomy; BMI, body mass index; %EWL, percentage of excess weight loss; %TBWL, percentage of total body weight loss; N/R, not reported; NIH, National Heart, Lung, and Blood Institute.

1

Considering Clavien Dindo grade I and II as minor adverse events, while grade III, IV and V as major adverse events

2

Obesity class I and II

3

Revised Cochrane Risk-Of-Bias (ROB) tool for randomized trials